AWM
AUPH icon

Accel Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Accel Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,045
Closed -$11.5K – 220
2023
Q1 		$11.5K Hold
1,045
– – ﹤0.01% 852
2022
Q4 		$4.51K Sell
1,045
-6,810
-87% -$39.5K ﹤0.01% 826
2022
Q3 		$59K Buy
7,855
+7,370
+1,520% +$63.8K 0.03% 331
2022
Q2 		$5K Hold
485
– – ﹤0.01% 801
2022
Q1 		$6K Hold
485
– – ﹤0.01% 774
2021
Q4 		$11K Buy
485
+135
+39% +$3.2K 0.01% 687
2021
Q3 		$8K Sell
350
-1,635
-82% -$25.9K 0.01% 670
2021
Q2 		$26K Buy
1,985
+1,500
+309% +$19.1K 0.02% 462
2021
Q1 		$6K Hold
485
– – ﹤0.01% 719
2020
Q4 		$7K Buy
+485
New +$7.06K 0.01% 662

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Accel Wealth Management's AUPH Position: Q2 2023 in Review

Accel Wealth Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 1,045 shares — an estimated $11.5K sold.

Accel Wealth Management first reported a position in AUPH in Q4 2020 and held it in 10 quarters. The position peaked at $59K in Q3 2022. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

  • Accel Wealth Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Accel Wealth Management sold 1,045 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $11.5K.
  • Accel Wealth Management first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Accel Wealth Management's Aurinia Pharmaceuticals position peaked at $59K in Q3 2022.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.